{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:03:39Z","timestamp":1791291819413,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2002,9,20]],"date-time":"2002-09-20T00:00:00Z","timestamp":1032480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Statistics in Medicine"],"published-print":{"date-parts":[[2002,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinical trials now often involve thousands of patients, and statisticians emphasize the importance of trial size in ensuring that \u2018correct\u2019 answers are obtained. However, when a good treatment appears for a disease that was hitherto untreatable \u2013 for example, oranges for scurvy or streptomycin for tuberculosis \u2013 only a small trial is needed. Large trials are only needed to demonstrate small effects. The meta\u2010analysis of small trials is often misleading, and may hide undesirable effects of individual drugs. The concept of equivalence between treatments is important, and while a statistically adequate equivalence trial may have to be very large, many clinicians will question the need for extreme statistical propriety. Clinical trials often do not reflect \u2018real world\u2019 practice, and the clinical relevance of a trial is more important than its size. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/sim.1284","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T03:58:14Z","timestamp":1034135894000},"page":"2807-2814","source":"Crossref","is-referenced-by-count":17,"title":["Size isn't everything"],"prefix":"10.1002","volume":"21","author":[{"given":"J. R.","family":"Hampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,9,20]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)72122-2"},{"key":"e_1_2_1_3_2","first-page":"9","article-title":"Twenty years on","author":"Smith E","year":"1960","journal-title":"Oxford Medical School Gazette"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702203360801"},{"key":"e_1_2_1_5_2","volume-title":"A Treatise of the Scurvy","author":"Lind J","year":"1753"},{"key":"e_1_2_1_6_2","first-page":"669","article-title":"Streptomycin treatment of pulmonary tuberculosis","volume":"2","author":"Medical Research Council Investigation","year":"1948","journal-title":"British Medical Journal"},{"key":"e_1_2_1_7_2","first-page":"77","volume-title":"Controlled Clinical Trials","author":"Hill AB","year":"1990"},{"key":"e_1_2_1_8_2","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,287 cases of suspected acute myocardial infarction","author":"ISIS\u20102 (Secondary International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Lancet"},{"key":"e_1_2_1_9_2","first-page":"397","article-title":"Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction","author":"Gruppo Italiano Per Lo Studio Della Streptochinasi Nell'Infarto Miocardico (GISSI)","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92656-6"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91893-D"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91590-7"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists' Collaboration","year":"1994","journal-title":"British Medical Journal"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708213370806"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-0620(85)80003-7"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198104023041401"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90831-K"},{"issue":"12","key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","article-title":"A randomized trial of propranolol in patients with acute myocardial infarction","volume":"247","author":"\u00df\u2010Blocker Heart Attack Trial Research Group","year":"1982","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92224-5"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710163371604"},{"key":"e_1_2_1_22_2","first-page":"167","article-title":"Variations in the use of coronary arteriography in the UK: the RITA trial coronary arteriogram register","volume":"88","author":"Henderson RA","year":"1995","journal-title":"Quarterly Journal of Medicine"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512213332503"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.293.6556.1204"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.81.6.598"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/oxfordjournals.eurheartj.a061845","article-title":"Metoprolol in acute myocardial infarction (MIAMI). A Randomised placebo\u2010controlled international trial","volume":"6","author":"The MIAMI Trial Research Group","year":"1985","journal-title":"European Heart Journal"},{"key":"e_1_2_1_27_2","first-page":"57","article-title":"Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction","author":"ISIS\u20101 (First International Study of Infarct Survival) Collaborative Group","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7101.159"},{"key":"e_1_2_1_29_2","first-page":"687","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study","volume":"343","author":"Stroke Prevention in Atrial Fibrillation Investigators","year":"1994","journal-title":"Lancet"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsim.1284","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.1284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:31:36Z","timestamp":1694604696000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.1284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9,20]]},"references-count":28,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2002,10,15]]}},"alternative-id":["10.1002\/sim.1284"],"URL":"https:\/\/doi.org\/10.1002\/sim.1284","archive":["Portico"],"relation":{},"ISSN":["0277-6715","1097-0258"],"issn-type":[{"value":"0277-6715","type":"print"},{"value":"1097-0258","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9,20]]}}}